NanoLogix CEO expects FDA to clear diagnostic tests for bacteria

06/12/2011 |

NanoLogix CEO Bret Barnhizer said the Ohio-based company expects to secure in the next few months FDA clearances for several diagnostic tests, which can rapidly detect a wide range of bacteria. One of the company's products is BioNanoPore technology, which is being tested in two clinical trials to determine its ability to spot Group B Streptococcus.

View Full Article in:

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Executive Officer
UCare Minnesota
Minneapolis, MN